| 刘 菲,张蓓蕾,岳 娟.可溶性间质表皮转化因子预测卵巢癌铂类耐药和预后研究[J].肿瘤学杂志,2025,31(11):952-958. |
| 可溶性间质表皮转化因子预测卵巢癌铂类耐药和预后研究 |
| Study on Soluble Cellular-Mesenchymal to Epithelial Transition Factor as a Predictor of Platinum Resistance and Prognosis in Ovarian Cancer |
| 投稿时间：2024-10-11 |
| DOI：10.11735/j.issn.1671-170X.2025.11.B005 |
|
 |
| 中文关键词: 卵巢肿瘤 间质表皮转化因子 铂类耐药 预后 |
| 英文关键词:ovarian neoplasms cellular-mesenchymal to epithelial transition factor platinum resistance prognosis |
| 基金项目:陕西省自然科学基础研究计划（2023-JC-YB-660） |
|
| 摘要点击次数: 8 |
| 全文下载次数: 1 |
| 中文摘要: |
| 摘 要：［目的］ 分析可溶性间质表皮转化因子（cellular-mesenchymal to epithelial transition factor，c-MET）与卵巢癌铂类耐药和生存预后的关系。［方法］ 纳入2019年1月至2023年3月期间65例原发性上皮性卵巢癌（epithelial ovarian cancer ，EOC）患者，患者术后完成至少6个疗程以铂类+紫杉醇为基础的辅助化疗。如果肿瘤在完成基于铂类化疗后6个月内复发，则临床上将其定义为铂类耐药。此外，纳入65名健康志愿者血液样本作为健康对照。采用酶联免疫吸附测定法检测血清可溶性c-MET水平。记录EOC患者的无进展生存期（progression-free survival，PFS）、总生存期（overall survival，OS）。［结果］ EOC患者基线［371.90（251.00，645.60）ng/mL］、化疗3个疗程后［546.54（262.60，809.90） ng/mL］血清可溶性c-MET水平均高于健康对照 ［239.80（176.50，286.40）ng/mL］，三组间存在统计学差异（H=31.134，P＜0.001）。FIGO Ⅲ～Ⅳ期患者基线血清可溶性c-MET水平相比较于FIGOⅠ～Ⅱ期患者更高［689.10（624.00，784.00）ng/mL vs 221.10（135.11，360.10）ng/mL，Z=-3.993，P＜0.001］。在EOC患者中，基线血清可溶性c-MET水平预测铂类耐药的受试者工作特征曲线下面积为0.862（95%CI：0.753～0.935）。基线血清可溶性c-MET≤371.90 ng/mL EOC患者的中位PFS（20.0个月 vs 16.0个月，χ2=10.779，P=0.001）、中位OS（24.0个月 vs 24.5个月，χ2=5.007，P=0.025）优于基线血清可溶性c-MET＞371.90 ng/mL患者。Cox多因素回归分析显示基线血清可溶性c-MET水平＞371.90 ng/mL为EOC患者PFS的独立危险因素（HR=2.689，95%CI：1.302~5.555，P=0.008）。［结论］ 血清可溶性c-MET检测可作为EOC患者诊断、治疗反应监测和预后生物标志物。基线血清可溶性c-MET高水平预示着铂类耐药和较差的生存预后，但仍需要更多机构研究来验证。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the association of soluble cellular-mesenchymal to epithelial transition factor (c-MET) with platinum resistance and survival in ovarian cancer patients. ［Methods］ Sixty-five patients with primary epithelial ovarian cancer (EOC) diagnosed between January 2019 and March 2023 were enrolled. All patients underwent primary surgery followed by at least six cycles of platinum-paclitaxel-based adjuvant chemotherapy. Platinum resistance was defined as disease recurrence within six months after completing platinum-based chemotherapy. Serum soluble c-MET levels were measured using enzyme-linked immunosorbent assay (ELISA) in 65 EOC patients (at baseline and after three chemotherapy cycles) and 65 healthy controls. Progression-free survival (PFS) and overall survival (OS) were recorded. ［Results］ Serum soluble c-MET levels were significantly higher in EOC patients at baseline ［371.90 (251.00， 645.60) ng/mL］ and after three chemotherapy cycles ［546.54 (262.60， 809.90) ng/mL］ compared to healthy controls ［239.80 (176.50， 286.40) ng/mL］ (H=31.134， P<0.001). Patients with FIGO stage Ⅲ~Ⅳ disease had higher baseline soluble c-MET levels than those with stage Ⅰ~Ⅱ patients［689.10 (624.00， 784.00) ng/mL vs 221.10 (135.11， 360.10) ng/mL， Z=-3.993， P<0.001］. Baseline soluble c-MET levels predicted platinum resistance with an area under the receiver operating characteristic curve (AUC) of 0.862 (95%CI： 0.753~0.935). Patients with baseline soluble c-MET ≤371.90 ng/mL had significantly longer median PFS (20.0 vs 16.0 months， χ2=10.779， P=0.001) and OS (24.0 vs 24.5 months， χ2=5.007， P=0.025) than those with baseline soluble c-MET > 371.90 ng/mL. Cox regression analysis identified baseline soluble c-MET >371.90 ng/mL as an independent risk factor for PFS (HR=2.689， 95%CI： 1.302~5.555， P=0.008). ［Conclusion］ Serum soluble c-MET shows promise as a diagnostic， treatment-response monitoring， and prognostic biomarker in EOC. Elevated baseline soluble c-MET levels are associated with platinum resistance and poorer survival outcomes. Further multi-institutional studies are warranted to validate its clinical utility. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |